HUP0001379A2 - Készítmény humán immundeficiencia vírus és más vírusfertőzések okozta betegségek antimikrobás megelőzésére és kezelésére - Google Patents

Készítmény humán immundeficiencia vírus és más vírusfertőzések okozta betegségek antimikrobás megelőzésére és kezelésére

Info

Publication number
HUP0001379A2
HUP0001379A2 HU0001379A HUP0001379A HUP0001379A2 HU P0001379 A2 HUP0001379 A2 HU P0001379A2 HU 0001379 A HU0001379 A HU 0001379A HU P0001379 A HUP0001379 A HU P0001379A HU P0001379 A2 HUP0001379 A2 HU P0001379A2
Authority
HU
Hungary
Prior art keywords
virus
treatment
echinacea
plant
preparation according
Prior art date
Application number
HU0001379A
Other languages
English (en)
Inventor
Meryl Squires
Original Assignee
Meryl Squires
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meryl Squires filed Critical Meryl Squires
Publication of HUP0001379A2 publication Critical patent/HUP0001379A2/hu
Publication of HUP0001379A3 publication Critical patent/HUP0001379A3/hu
Publication of HU226910B1 publication Critical patent/HU226910B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Atalálmány tárgya készítmény, amely vitaminból és növényből áll.Atalálmány lényege, hőgy a vitamin főlsavat, a növény pedig azEchinacea nemzetséghez tartőzó lágyszárú gyógynövényt, példáűlEchinacea Echinacea pűrpűreát tartalmaz. A találmány szerintikészítmény célszerűen egy másődik növényt is tartalmaz, a Cőmmiphőranemzetségből. Atalálmány szerinti készítmény tartalmaz célszerűenkvaterner ammóniűmsót, példáűl benzalkóniűm-klőridőt felületaktívanyagként. A találmány szerinti készítmény alkalmashűmánimműndeficiencia-vírűs és más fertőzések őkőzta betegségekantimikrőbás megelőzésére és kezelésére. ŕ
HU0001379A 1997-03-26 1998-03-24 Készítmény humán immundeficiencia vírus és más vírusfertõzések okozta betegségek antimikrobás megelõzésére és kezelésére HU226910B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/824,041 US6350784B1 (en) 1996-02-12 1997-03-26 Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
PCT/US1998/005792 WO1998042188A1 (en) 1997-03-26 1998-03-24 Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases

Publications (3)

Publication Number Publication Date
HUP0001379A2 true HUP0001379A2 (hu) 2000-08-28
HUP0001379A3 HUP0001379A3 (en) 2000-11-28
HU226910B1 HU226910B1 (hu) 2010-03-01

Family

ID=25240459

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001379A HU226910B1 (hu) 1997-03-26 1998-03-24 Készítmény humán immundeficiencia vírus és más vírusfertõzések okozta betegségek antimikrobás megelõzésére és kezelésére

Country Status (30)

Country Link
US (3) US6350784B1 (hu)
EP (1) EP0980203B1 (hu)
JP (2) JP2001527541A (hu)
KR (1) KR100403418B1 (hu)
CN (1) CN1258191A (hu)
AP (1) AP1163A (hu)
AT (1) ATE358418T1 (hu)
AU (1) AU727339B2 (hu)
BG (1) BG63612B1 (hu)
BR (1) BR9807892A (hu)
CA (1) CA2285394C (hu)
CZ (1) CZ298406B6 (hu)
DE (1) DE69837474T2 (hu)
DK (1) DK0980203T3 (hu)
EA (1) EA002423B1 (hu)
EE (1) EE9900436A (hu)
ES (1) ES2285765T3 (hu)
GE (1) GEP20022749B (hu)
HU (1) HU226910B1 (hu)
IL (1) IL132003A (hu)
IS (1) IS5191A (hu)
NO (1) NO325017B1 (hu)
NZ (1) NZ500002A (hu)
OA (1) OA11198A (hu)
PL (1) PL196036B1 (hu)
RS (1) RS49963B (hu)
SK (1) SK285810B6 (hu)
TR (1) TR199902674T2 (hu)
UA (1) UA65563C2 (hu)
WO (1) WO1998042188A1 (hu)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350784B1 (en) * 1996-02-12 2002-02-26 Meryl J. Squires Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
US9662360B2 (en) 2008-10-09 2017-05-30 Meritus Corporation Treatment of herpes, pseudomonas, staph, and hepatitis
US20090191288A1 (en) * 1996-02-12 2009-07-30 Squires Meryl J Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
JP4873785B2 (ja) 1999-03-26 2012-02-08 サンスター株式会社 Ｉ型アレルギー予防乃至治療用組成物
CA2373844A1 (en) * 1999-06-30 2001-01-11 Unilever Plc Cosmetic skin care compositions containing cumic alcohol
CA2375647A1 (en) 1999-07-08 2001-01-18 Patrick T. Prendergast Use of flavones, coumarins and related compounds to treat infections
US6759434B2 (en) 1999-09-22 2004-07-06 B. Ron Johnson Anti-infective compositions, methods and systems for treating disordered tissue
US8173709B2 (en) * 1999-09-22 2012-05-08 Quadex Pharmaceuticals, Llc Anti-infective methods for treating pathogen-induced disordered tissues
US6211243B1 (en) 1999-09-22 2001-04-03 B. Ron Johnson Methods for treating cold sores with anti-infective compositions
WO2001034170A2 (en) * 1999-11-04 2001-05-17 Maria Antoinette Brandes Phytotherapeutic composition
US7147859B2 (en) * 2000-05-15 2006-12-12 Laboratorios Biosintetica Ltda. Application of phytosterols (and their isomers), folic acid, cyanocobalamin and pyridoxin in dietetic (alimentary) fibers
DE60033699D1 (de) * 2000-06-19 2007-04-12 Skopichenko Dettwiler Victoria Kräuterzusammensetzung enthaltend calendula und eucalyptus für die behandlung und heilung von erkrankungen
AU2002219472A1 (en) * 2001-01-02 2002-07-16 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
IL143318A0 (en) * 2001-05-23 2002-04-21 Herbal Synthesis Corp Herbal compositions for the treatment of mucosal lesions
AU2002367976B2 (en) * 2001-06-05 2007-06-21 The Regents Of The University Of Michigan Nanoemulsion vaccines
US7923023B2 (en) * 2002-02-25 2011-04-12 Astech International LLC Method and composition for delivery of medicants to animals
CH696628A5 (de) * 2002-02-26 2007-08-31 Eprova Ag Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der
GB0212405D0 (en) * 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
US7115563B2 (en) 2002-05-29 2006-10-03 Insignion Holding Limited Composition and its therapeutic use
US8492443B2 (en) * 2002-07-08 2013-07-23 Joe S. Wilkins, Jr. Treatment for herpes simplex virus and other infectious diseases
FR2843125B1 (fr) * 2002-08-02 2012-11-16 Coletica Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs
EP2387882A3 (en) * 2002-08-12 2012-10-31 Lonza Inc. Antimicrobial compositions comprising cinnamaldehyde
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
IL153124A (en) * 2002-11-27 2010-06-30 Herbal Synthesis Corp Solid composition that can be glued to the lining
US20050036972A1 (en) * 2003-03-10 2005-02-17 Hy-Gene Biomedical Corporation System for managing pathogens and irritants and monitoring usage of anti-bacterial formulations
GB0326518D0 (en) * 2003-11-13 2003-12-17 Compton Developments Ltd Anti-cancer compounds
WO2005046695A1 (en) * 2003-11-17 2005-05-26 Maria Waithira Njuguna Injection vitamin b complex for treatment of non specific vaginitis (bacterial vaginitis)
US20080124408A1 (en) * 2004-07-07 2008-05-29 Mediherb Holdings Ltd. Echinacea Formulation
WO2006031230A1 (en) * 2004-09-10 2006-03-23 Hy-Gene Biomedical Corporation System for managing pathogens and irritants and monitoring usage of anti-bacterial formulations
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US20080038295A1 (en) * 2006-04-13 2008-02-14 Regents Of The University Of Michigan Compositions and methods for orthopox virus vaccination
US9839685B2 (en) * 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
JP2007332126A (ja) * 2006-06-16 2007-12-27 Teikyo Univ ヒトおよび愛玩動物のための抗白癬入浴剤
CN101697966B (zh) * 2007-01-08 2011-10-19 杭州民生药业有限公司 蓬莪术环二烯在制备治疗由病毒引起的疾病的药物中的应用
DE102007029042A1 (de) * 2007-06-21 2008-12-24 Analyticon Discovery Gmbh Pharmazeutische Zusammensetzung mit einem Trihydroxychromenone-Derivate
US8637094B2 (en) 2007-07-18 2014-01-28 Iraj E. Kiani Composition and method for treating viral conditions
US7850998B2 (en) * 2007-07-18 2010-12-14 Kiani Iraj E Method of treating viral conditions
US7700137B1 (en) 2007-07-18 2010-04-20 Kiani Iraj E Anti-viral compositions and method
WO2009143524A2 (en) * 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion vaccines
CA2731445C (en) * 2008-07-22 2018-05-15 Izun Pharmaceuticals, Inc. Topical anti-inflammatory combination having actives of sambucus nigra, centella asiatica or echinacea purpurea
CH699653B1 (de) * 2008-09-08 2010-05-14 Bioforce Ag Roggwil Tg Zubereitung zur Prävention und/oder Behandlung und/oder Verhinderung der Weiterverbreitung von Atemwegserkrankungen.
WO2010091280A1 (en) * 2009-02-06 2010-08-12 Alcon Research, Ltd. N-halogenated amino acid formulations comprising phosphine or amine oxides
US20100303935A1 (en) * 2009-05-29 2010-12-02 Squires Meryl J Medicinal Composition
ES2566646T3 (es) * 2009-06-16 2016-04-14 The Regents Of The University Of Michigan Vacunas en nanoemulsión
EP2324840B1 (en) * 2009-11-18 2019-03-20 Croda Italiana S.p.A. Production of caffeoylquinic acids from plant cell cultures of echinacea angustifolia
EP2523675B1 (en) * 2010-01-11 2019-03-06 Vitro-Bio Sarl New synergistic compositions for the treatment of topical viral infections
AU2011227202A1 (en) * 2010-03-17 2012-10-04 Arbonne International Llc Oral supplement
WO2012069605A1 (en) 2010-11-26 2012-05-31 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Novel e,e-diene compounds and their use as medicaments and cosmetics
DK2500026T3 (da) * 2011-03-17 2013-08-26 Sonia Pharma Gmbh Behandling af menopausale symptomer som moderne indikation for myrra
US8287924B2 (en) 2011-03-17 2012-10-16 Sonia Pharma Gmbh Treatment of menopausal symptoms as novel indication for myrrh
JP5519879B2 (ja) * 2011-03-17 2014-06-11 ソニア ファーマ ゲーエムベーハー ミルラの新規な適用としての更年期症状としての膣の委縮の処置
KR101334348B1 (ko) * 2011-12-21 2013-11-29 한국생명공학연구원 바이러스 억제 활성을 갖는 플라보노이드 화합물
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum
US9549930B2 (en) 2013-03-14 2017-01-24 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered and/or prodromal stage tissue
US9125911B2 (en) 2013-03-14 2015-09-08 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered tissues
PT2792389T (pt) * 2013-04-17 2020-01-20 Global Health Solutions Ag Composição farmacêutica antiviral contendo um extracto de junco picante
CA2955981C (en) 2014-07-22 2022-10-25 Ralco Nutrition, Inc. Antiviral compositions comprising one or more essential oils
CN106496202B (zh) * 2015-09-06 2019-08-06 中国海洋大学 一种生物碱类化合物及其制备方法与作为抗单纯疱疹ⅰ型病毒剂的应用
US20200179299A1 (en) 2018-12-07 2020-06-11 Global Biolife Inc. Composition and method of controlling infectious diseases with functional fragrances
EP3894018A4 (en) * 2018-12-11 2022-11-02 Glyciome, LLC TOPICAL, ISOTONIC COMPOSITIONS FOR GENITAL USE
KR102416208B1 (ko) * 2020-01-08 2022-07-01 건국대학교 산학협력단 발효된 선복화 추출물을 포함하는 항인플루엔자 바이러스용 조성물
IT202000018970A1 (it) * 2020-08-03 2022-02-03 Asoltech Srl Composizione a base di mirra
LU102656B1 (de) 2021-03-11 2022-09-12 Prosecur Gmbh Flüssiges Nahrungsergänzungsmittel zur Immunstimulation, Verfahren zu dessen Herstellung sowie Verwendung
CN115414349B (zh) * 2022-08-26 2023-11-03 武汉科前生物股份有限公司 芹菜素在制备治疗猫鼻支气管炎药物中的用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4283421A (en) * 1979-12-19 1981-08-11 Ray Frank F Anti-viral treatment
US4760079A (en) * 1983-01-10 1988-07-26 Baltech, Inc. Treatment of diseases caused by herpes viruses
US4935448A (en) * 1983-01-10 1990-06-19 Baldone Joseph A Treatment of diseases caused by herpes viruses
US4661354A (en) * 1984-06-21 1987-04-28 Finnerty Edmund F Topical treatment of herpes simplex with a zinc sulfate-camphor water solution
US4797420A (en) * 1984-08-14 1989-01-10 Jabco Manufacturing, Inc. Disinfectant formulation and method of use
US4585656A (en) * 1984-08-20 1986-04-29 Rosenthal Harold R Treatment of herpes
DE3521143A1 (de) * 1985-06-13 1986-12-18 Robugen Gmbh Arzneimittel zur behandlung schwerer herpes-infektionen
DE3522075A1 (de) * 1985-06-20 1987-01-02 Lomapharm Rudolf Lohman Gmbh K Sesquiterpenverbindungen, verfahren zu ihrer isolierung und arzneimittel, enthaltend diese verbindungen
EP0213099A3 (de) * 1985-08-23 1989-07-19 Cederroth Nordic Aktiebolag Mittel mit antiphlogistischer, immunstimulierender und zytoprotektiver Wirkung, ihre Herstellung und pharmazeutische Verwendungen
DE3533563A1 (de) * 1985-09-20 1987-03-26 Michael Birzer Mep-aids mittel
FR2620698B1 (fr) * 1987-09-23 1990-08-10 Atlantic Pharma Prod Fluorure d'ammonium quaternaire et son application dans une substance inhibitrice ou destructrice d'etres vivants unicellulaires
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
DE4017091A1 (de) 1990-05-27 1991-11-28 Walter Dr Mach Molekuelverbundsystem zur kontra-eskalativen therapie viraler infektionskrankheiten
US6348503B1 (en) * 1996-02-12 2002-02-19 Meryl J. Squires Method and topical treatment composition for herpesvirus hominis
US6355684B1 (en) * 1990-10-11 2002-03-12 Meryl J. Squires Antimicrobial treatment for herpes simplex virus and other infectious diseases
US6350784B1 (en) * 1996-02-12 2002-02-26 Meryl J. Squires Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
US5248503A (en) * 1992-01-03 1993-09-28 Emanuel King Rosalba Herbal dietary supplement
US5461029A (en) * 1992-04-24 1995-10-24 American Cyanamid Company Method of treating herpes viral infections using HBNF and MK proteins
US5455033A (en) * 1993-05-21 1995-10-03 Degree/Silverman M.D. Inc. Medicinal composition for treatment of inflammation
NL9500216A (nl) 1995-02-06 1996-09-02 Bio Pharma Sciences Bv Farmaceutische samenstelling voor de behandeling van herpes.
US5876728A (en) * 1995-02-15 1999-03-02 Howard David Kass Natural composition extracted from plants used in the treatment of cancer
AU679162B3 (en) * 1995-11-21 1997-06-19 Stolair Pty Ltd Therapeutic compositions

Also Published As

Publication number Publication date
SK131899A3 (en) 2000-12-11
ES2285765T3 (es) 2007-11-16
CN1258191A (zh) 2000-06-28
WO1998042188A1 (en) 1998-10-01
BR9807892A (pt) 2000-02-22
YU48099A (sh) 2002-03-18
NZ500002A (en) 2001-09-28
NO994639D0 (no) 1999-09-24
HUP0001379A3 (en) 2000-11-28
TR199902674T2 (xx) 2000-02-21
AP1163A (en) 2003-06-30
BG63612B1 (bg) 2002-07-31
AP9901661A0 (en) 1999-09-30
CA2285394A1 (en) 1998-10-01
SK285810B6 (sk) 2007-08-02
DE69837474D1 (de) 2007-05-16
IL132003A (en) 2005-08-31
EA199900773A1 (ru) 2000-10-30
IS5191A (is) 1999-09-23
EP0980203A4 (en) 2004-05-06
DK0980203T3 (da) 2007-07-30
JP2001527541A (ja) 2001-12-25
KR100403418B1 (ko) 2003-10-30
IL132003A0 (en) 2001-03-19
ATE358418T1 (de) 2007-04-15
OA11198A (en) 2003-05-30
EP0980203B1 (en) 2007-04-04
US20060024393A1 (en) 2006-02-02
US6350784B1 (en) 2002-02-26
RS49963B (sr) 2008-09-29
CA2285394C (en) 2013-01-08
PL196036B1 (pl) 2007-11-30
HU226910B1 (hu) 2010-03-01
US20030104082A1 (en) 2003-06-05
CZ298406B6 (cs) 2007-09-26
KR20010005603A (ko) 2001-01-15
EP0980203A1 (en) 2000-02-23
NO994639L (no) 1999-11-24
BG103786A (bg) 2000-10-31
GEP20022749B (en) 2002-08-26
DE69837474T2 (de) 2007-12-13
JP2000119188A (ja) 2000-04-25
UA65563C2 (uk) 2004-04-15
EE9900436A (et) 2000-04-17
NO325017B1 (no) 2008-01-14
CZ336899A3 (cs) 2000-07-12
PL336168A1 (en) 2000-06-05
AU727339B2 (en) 2000-12-07
US7071233B2 (en) 2006-07-04
EA002423B1 (ru) 2002-04-25
AU6771898A (en) 1998-10-20

Similar Documents

Publication Publication Date Title
HUP0001379A2 (hu) Készítmény humán immundeficiencia vírus és más vírusfertőzések okozta betegségek antimikrobás megelőzésére és kezelésére
HUP9901144A2 (hu) Hatóanyagként klopidogrel és egy antitrombotikum új kombinációját tartalmazó gyógyszerkészítmények
HUP0002196A2 (hu) Gyógyhatású táplálékkiegészítő cukorbetegek részére
IL143512A (en) Azabicycloalkanes, pharmaceuticals including them and their use in the manufacture of drugs for the prevention or treatment of infection by the immunodeficiency virus
RU92004423A (ru) Препарат из растений curcuma
WO2004096818A3 (en) Method and compositions for identifying anti-hiv therapeutic compounds
CA2213989A1 (en) External preparation for topical administration
NO952863L (no) Farmasöytiske preparater av fluoxetin
GB0129260D0 (en) Pharmaceutical compositions and their uses
CA2317044A1 (en) Medicament for neurodegenerative diseases
EP0750908A4 (en) REMEDY FOR INFECTIOUS DISEASES
NO20053348L (no) Farmasoytisk sammensetning for behandling av virusangrep.
MX9308005A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
HUP0202745A2 (hu) Profilaktikus és terápiás szerek szembetegségek kezelésére
CA2213794A1 (en) Preventive or therapeutic drug for alzheimer's disease
CA2100066A1 (en) Michellamines useful as antiviral agents, composition and method of treatment
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
HK1075390A1 (en) Citalopram for the treatment of elevated blood pressure
IL102815A (en) Pharmaceutical compositions for the treatment of infection caused by the human immunodeficiency virus
WO2001030325A3 (en) Use of a bis-peroxovanadium compound for the treatment of immunosuppressed patients
YU9099A (en) Use of 2-phenyl-1,2-benzisoselenazol-3(2h)-one for producting a pharmaceutical preparation for treatment of the alzheimer's disease
GB2362827A (en) Pharmaceutical preparation for treating viral infections
AP2002002644A0 (en) Antiviral and antibacterial pharmaceutical preparation "armenicum" and its use for treatment of infectious diseases
ATE212839T1 (de) Hämoregulatorische verbindungen
WO2002009677A3 (en) Method to treat infectious diseases and/or to enhance antimicrobial efficacy of drugs

Legal Events

Date Code Title Description
FH92 Termination of representative

Representative=s name: MESZAROS GYULANE, BUDAPATENT SZABADALMI ES VED, HU

FD9A Lapse of provisional protection due to non-payment of fees
NF4A Restoration of patent protection
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): MESZAROS GYULANE, BUDAPATENT SZABADALMI ES VEDJEGY IRODA KFT., HU

Representative=s name: IFJ. SZENTPETERI ADAM SZABADALMI UEGYVIVOE S.B, HU

NF4A Restoration of patent protection
MM4A Lapse of definitive patent protection due to non-payment of fees
NF4A Restoration of patent protection
MM4A Lapse of definitive patent protection due to non-payment of fees
NF4A Restoration of patent protection
MM4A Lapse of definitive patent protection due to non-payment of fees
NF4A Restoration of patent protection
MM4A Lapse of definitive patent protection due to non-payment of fees